5 results
The objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium plus olodaterol fixed dose combination compared with the individual components tiotropium and olodaterol (delivered by…
We aim to investigate whether this damage results from altered pulmonary blood flow patterns and related increases in shear stress and vascular remodelling. To test our hypothesis we will make use of novel techniques to quantify pulmonary perfusion…
The primary objective of this study is to compare the effects of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 / 5 µg ; 5 / 5 µg) with tiotropium (5 µg), olodaterol (5 µg) and placebo on lung-hyperinflation and endurance time…
The primary objective of the trial is to determine the 24-hour FEV1-time profile of tiotropium + olodaterol FDC (2.5/5 µg, 5/5 µg), administered once daily by the RESPIMAT Inhaler, after 6 weeks of treatment.
The proposed multi-center population-based open-label randomized controlled trial with blinded outcome assessment will examine if metformin slows AAA growth in patients with small AAAs who do not have diabetes. Primary objective To examine if up to…